Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma

A single‐institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer.

[1]  J. Bar-ziv,et al.  Complete response of brain metastases originating in breast cancer to capecitabine therapy. , 2003, The Israel Medical Association journal : IMAJ.

[2]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Michael L. Wang,et al.  Capecitabine for 5‐Fluorouracil‐Resistant Brain Metastases From Breast Cancer , 2001, American journal of clinical oncology.

[4]  R. Demicheli,et al.  Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screening. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Lezak.  Neuropsychological assessment, 3rd ed. , 1995 .

[6]  J. Wolchok,et al.  Systemic chemotherapy. , 2000, Clinics in plastic surgery.

[7]  C. Nowinski,et al.  Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. , 2002, Archives of physical medicine and rehabilitation.

[8]  W. Curran,et al.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Deangelis,et al.  Radiation‐induced dementia in patients cured of brain metastases , 1989, Neurology.

[10]  J. Raizer,et al.  A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases , 2004, Journal of Neuro-Oncology.

[11]  Emil Frei,et al.  Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide , 1960 .

[12]  J. J. Ryan,et al.  Wechsler Adult Intelligence Scale-III , 2001 .

[13]  D. Kirsch,et al.  Brain metastases in patients with breast cancer: new horizons. , 2005, Clinical breast cancer.

[14]  D. Kondziolka,et al.  Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients , 2001, Neurology.

[15]  O. Dalesio,et al.  Response of brain metastases from breast cancer to systemic chemotherapy , 1992, Cancer.

[16]  R. McKinstry,et al.  Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. , 2003, Neuroimaging clinics of North America.

[17]  D. Antonadou,et al.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Possinger,et al.  Chemotherapy for Breast Cancer Brain Metastases , 2002, Oncology Research and Treatment.

[19]  P. Kosmidis,et al.  Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Ralph H. B. Benedict,et al.  Hopkins Verbal Learning Test—Revised: Normative data and analysis of inter-form and test–retest reliability. , 1998 .

[21]  S. Dahrouge,et al.  Response of brain metastases from breast cancer to megestrol acetate: A case report , 2005, Journal of Neuro-Oncology.

[22]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.